Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling

This study examined rates of genetic testing in two cohorts of publicly insured individuals who have newly prescribed medication with FDA pharmacogenomic labeling guidance. Genetic testing was rare (4.4% and 10.5% in Medicaid and Medicare cohorts, respectively) despite the fact that all participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, John, Bhattacharya, Kaustuv, Ramachandran, Sujith, Lee, Aaron, Bentley, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883752/
https://www.ncbi.nlm.nih.gov/pubmed/33589791
http://dx.doi.org/10.1038/s41397-021-00211-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883752/
https://www.ncbi.nlm.nih.gov/pubmed/33589791
http://dx.doi.org/10.1038/s41397-021-00211-1

Ejemplares similares